PRDX1 promotes clear cell renal cell carcinoma progression by modulating EGFR-dependent AKT pathway activation
Frontiers in Pharmacology · 17.04.2026 · 17
DOI: 10.3389/fphar.2026.1741879 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 17.04.2026. Verfasst von Zhi Liang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Renal cell carcinoma (RCC) is a highly heterogeneous malignant tumor, characterized by a globally increasing incidence and mortality rate. Although surgical resection serves as the standard treatment for localized RCC, recurrence and metastasis remain major clinical challenges. Based on patient sample analysis and signaling pathway investigation, the present study identifies peroxiredoxin 1 (PRDX1) as a potential therapeutic target for RCC.
Methods
Patient microarray analysis, combined with data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, revealed the expression pattern of PRDX1 in clear cell renal cell carcinoma (ccRCC) and confirmed its prognostic and diagnostic significance. Cell proliferation was evaluated using Cell Counting Kit-8 (CCK-8) assay, while cell motility was assessed via wound healing and transwell assays. Gene expression profiles and signaling pathways were analyzed through bioinformatics approaches including Western blot, immunohistochemistry and immunoprecipitation. A xenograft mouse model was utilized to investigate the in vivo effects of PRDX1.
Results
The analysis of 90 pairs of ccRCC samples demonstrated that elevated PRDX1 expression was significantly associated with higher malignancy in ccRCC and correlated with tumor prognosis and clinical stage. Comprehensive bioinformatics analysis identified a close relationship between PRDX1 inhibition and relative epidermal growth factor receptor (EGFR) pathways. Mechanistically, co-immunoprecipitation (Co-IP) assays revealed that PRDX1 could act as a molecular chaperone by binding to the juxta-membrane (JM) domain of EGFR to induce EGFR phosphorylation. The downregulation of PRDX1 significantly reduced their proliferation and migration capacities in renal cell lines ACHN and 786-O, whereas PRDX1 overexpression exerted the opposite effect. Importantly, the inhibitory effects of PRDX1 knockdown on ccRCC could be attenuated by EGF activation in vitro , as well as the oncogenic functions enhanced by increasing PRDX1 was blocked by gefitinib, a specific inhibitor of EGFR. Treatment with PRDX1 inhibitor showed that PRDX1 inhibition restrain the growth and metastasis of ccRCC.
Conclusion
In summary, the findings of this study revealed a novel role of PRDX1 in triggering ccRCC progression by inducing the phosphorylation of EGFR, supporting that PRDX1 may serve as a potential therapeutic target for the clinical management of ccRCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China.
- Department of Pharmacy, The First People's Hospital of Foshan (Foshan Hospital Affiliated to Southern University of Science and Technology), School of Medicine, Southern University of Science and Technology, Foshan, Gua…
- Office of the Ethics Committee of Guangzhou First People's Hospital, Southern University of Science and Technology, Guangzhou, Guangdong, China.
Zitieren
APA
Liang, Z., Lin, X., Zeng, S., Wu, L., Dong, Y., Zhang, C., Li, M., Zhu, F., Chen, L., & Ni, S. (2026). PRDX1 promotes clear cell renal cell carcinoma progression by modulating EGFR-dependent AKT pathway activation. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1741879
Vancouver
Liang Z, Lin X, Zeng S, Wu L, Dong Y, Zhang C, et al. PRDX1 promotes clear cell renal cell carcinoma progression by modulating EGFR-dependent AKT pathway activation. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1741879
BibTeX
@article{Liang2026,
author = {Liang, Zhi and Lin, Xiaochun and Zeng, Shen and Wu, Lili and Dong, Yujun and Zhang, Chen and Li, Mei and Zhu, Fudi and Chen, Lu and Ni, Suiqin},
title = {PRDX1 promotes clear cell renal cell carcinoma progression by modulating EGFR-dependent AKT pathway activation},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1741879}
}
EUVIMED